Journal Home
Search for

Volume 53, Issue 3, Supplement 3, Pages S56-S63 (March 2009)


View previous. 11 of 19 View next.

Disease Management Programs for CKD Patients: The Potential and Pitfalls

Michael V. Rocco, MD, MSCECorresponding Author Informationemail address

Disease management describes the use of a number of approaches to identify and treat patients with chronic health conditions, especially those that are expensive to treat. Disease management programs have grown rapidly in the United States in the past several years. These programs have been established for patients with chronic kidney disease (CKD), but some have been discontinued because of the high cost of the program. Disease management programs for CKD face unique challenges. Identification of patients with CKD is hampered by incomplete use of the International Classification of Diseases, Ninth Revision (ICD-9) codes for CKD by physicians and the less than universal use of estimated glomerular filtration rate from serum creatinine measurements to identify patients with an estimated glomerular filtration rate less than 60 mL/min/1.73 m2. CKD affects multiple organ systems. Thus, a comprehensive disease management program will need to manage each of these aspects of CKD. These multiple interventions likely will make a CKD disease management program more costly than similar disease management programs designed for patients with diabetes mellitus, congestive heart failure, or other chronic diseases. The lack of data that can be used to develop effective disease management programs in CKD makes it difficult to determine goals for the management of each organ system affected by CKD. Finally, long periods of observation will be needed to determine whether a particular disease management program is effective in not only improving patient outcomes, but also decreasing both resource use and health care dollars. This long-term observation period is contrary to how most disease management contracts are written, which usually are based on meeting goals during a 1- to 3-year period. Until these challenges are resolved, it likely will be difficult to maintain effective disease management programs for CKD.

Wake Forest University School of Medicine, Winston-Salem, NC

Corresponding Author InformationAddress correspondence to Michael V. Rocco, MD, MSCE, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1053

PII: S0272-6386(08)01745-9

doi:10.1053/j.ajkd.2008.07.058


View previous. 11 of 19 View next.